Maze Therapeutics, Inc. leverages human genetics and functional genomics to discover and develop novel therapeutics. The company's proprietary Compass platform integrates genetic data to identify genetic modifiers that influence disease progression, informing all phases of its drug discovery process. Its clinical pipeline is primarily focused on chronic kidney diseases and metabolic conditions. Lead programs include MZE829, an oral small molecule inhibitor of APOL1 for APOL1-mediated kidney disease, and MZE782, an inhibitor targeting SLC6A19 for phenylketonuria and chronic kidney disease. The company also engages in strategic partnerships to advance additional research programs in areas such as Pompe disease and neurological disorders.
